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Diabetes-related lower-extremity amputation 
incidence and risk factors: a prospective 
seven-year study in Costa Rica
Adriana Laclé1 and Luis F. Valero-Juan2
Objective. To analyze the incidence and determinants of lower-extremity amputation 
(LEA) in people with diabetes in a low-income community in Costa Rica.
Methods. Data on LEA incidence were collected during a seven-year follow-up (2001–
2007) in a diabetes patient cohort (n = 572). Risk factors were analyzed using the Cox 
proportional hazards regression model and baseline variables from the year 2000 (socio- 
demographic characteristics, comorbidity, metabolic control, treatment, and chronic micro-
vascular complications).
Results. LEA incidence was 6.02 per 1 000 person-years (8.65 in men and 4.50 in women). 
Known risk factors (sex, years of diabetes, elevated glycated hemoglobin [HbA1c], retinopathy, 
insulin therapy, and prior amputation) were highly significant. 
Conclusions. Those most likely to undergo LEA among Costa Rican diabetic patients were 
men with 10 or more years of diabetes and average HbA1c ≥ 8% who used insulin and had 
diabetic retinopathy. Patients on insulin therapy were at greatest risk, especially those with a 
previous amputation. Diabetic patients with the above-mentioned profile should be considered 
to be at very high risk of LEA and followed closely by the health care system. 
Diabetes mellitus, type 2; lower extremity; amputation; risk factors; diabetes 
complications; Costa Rica. 
abstract
Key words
Diabetes mellitus type 2 (diabetes) is 
currently considered a pandemic, af-
fecting both developed and develop-
ing countries. This disease is largely 
associated with economic development, 
urbanism, and an aging population (1, 
2). In recent years, diabetes has attracted 
increasing concern worldwide because 
of its impact on the quality of life of 
those with the disease, and their family 
members; the growing costs to national 
health systems; and the indirect costs of 
the productivity losses associated with 
diabetes-related disability and prema-
ture death—all of which are related to 
diabetes chronic complications. Diabetes 
is the cause of approximately 66% of 
nontraumatic lower-extremity amputa-
tions (LEAs) and 30%–45% of renal fail-
ure cases requiring renal replacement 
therapy (dialysis). It is also the leading 
cause of blindness in adults (3–5).
Diabetic peripheral neuropathy, which 
can cause ulceration gangrene, leading to 
amputation, is one of the most frequent 
chronic complications of the disease (6). 
This condition occurs among 60%–70% 
of people who have been diagnosed with 
diabetes for 10 or more years. The rela-
tive risk of neuropathy is at least seven 
times higher and the risk of LEA 18–30 
times higher among those with diabetes 
versus the general population (6, 7). Foot 
ulceration is found prior to 85% of am-
putations among diabetic patients, and 
about 25% of diabetic amputees require 
a contralateral amputation. The survival 
rate for diabetic patients following am-
putation is only about 50% at three years 
(7–9). Diabetes-related LEA is related to 
age, years of diabetes, and poor meta-
bolic control of the disease (8).
In Costa Rica, diabetes has a high 
prevalence in the adult population (ap-
proximately 8%) (10) and is the most 
costly disease for the Social Security 
system (Caja Costarricense de Seguro So-
cial, CCSS) (11). Despite the fact that all 
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diabetes chronic complications, includ-
ing LEA, have a great impact on diabetic 
individuals as well as society as a whole, 
to the best of the authors’ knowledge no 
study to date has analyzed the incidence 
and risk factors of LEA in Costa Rica’s 
diabetic population. To help fill this gap, 
the current study analyzed data on inci-
dence of LEA collected over a seven-year 
follow-up and baseline characteristics 
of a cohort of diabetic patients in a low-
income community in Costa Rica.
MATERIALS AND METHODS 
This prospective study was conducted 
at the primary health care level in San 
José Province, Costa Rica, from 2001–
2007. The research was approved by the 
ethics committee of the University of 
Costa Rica.
Study population 
The cohort of diabetic patients (n = 
572) was identified at the primary health 
care level in the year 2000 in Health Area 
3 of Desamparados (“Desamparados 3”), 
a marginal urban health area (12). Based 
on its epidemiological surveillance data 
for the year 1999, 399 persons with dia-
betes were already receiving primary 
care attention regularly. New diabetic 
patients were diagnosed in 2000 through 
a screening of adults aged 20 years and 
older living in the area (n = 15 827) using 
the 1997 American Diabetes Association 
(ADA) criteria. Four screening strategies 
were used: 1) opportunistic screening 
by physicians during regular checkups; 
2) selective screening by primary health 
care technical assistants during their 
yearly round of home surveillance vis-
its; 3) screening of captive populations 
(nursing home residents, factory work-
ers, etc.) during programmed visits; and 
4) screening at community health fairs 
and national health activities such as 
World Diabetes Day (November 14). The 
screening consisted of a fasting glucose 
test administered to all adults with at 
least one risk factor for diabetes. A total 
of 173 individuals were diagnosed with 
diabetes with this strategy.
At baseline (the year 2000), the cohort 
was characterized as predominantly fe-
male (63.1%) with a low level of educa-
tion (35.0% with only a third-grade level 
or less education, and 16.3% with no 
schooling) and middle- or lower-level 
income (21.4% were insured by the state 
and 6.7% were uninsured). More than 
46.9% were 65 years old or older. Over-
all, the cohort’s metabolic control was 
poor (more than 60% had an average 
glycated hemoglobin [HbA1c] level ≥ 
8%), with no differences between sexes. 
There was a high prevalence of asso-
ciated diseases, such as hypertension 
(58%), and overweight-obesity (70.7%), 
both of which were statistically higher 
in women. There were no statistical dif-
ferences by sex for dyslipidemia (78.8%), 
ischemic heart disease (21%), or myocar-
dial infarction (6.7%). About 75% of the 
cohort experienced diabetes onset before 
age 60; among those patients, average 
number of years with diabetes was 7. 
There was a high prevalence of second-
ary complications of diabetes, including 
retinopathy (19.6%), neuropathy (30.6%), 
and nephropathy (33.6%) (13). For the 
most severe complications of neuropa-
thy, such as foot ulcers and amputations, 
there was a prevalence of 2.5%. 
Procedures 
Follow-up of the study cohort was 
conducted for seven years (2001–2007) 
and included 1) review of patients’ med-
ical records every two years during med-
ical checkups at the primary care level 
of the Costa Rican health system, and 2) 
determination of the presence or absence 
of LEA, and (when present) the level 
of amputation. For the purposes of this 
study, LEA was defined as loss of some 
part of the lower extremity, excluding 
amputation due to traumatic causes. 
Statistical analysis 
Baseline variables from 2000 (socio-
demographic characteristics, comor-
bidity, metabolic control, and chronic 
microvascular complications) were ana-
lyzed by presence or absence of LEA 
during the seven-year follow-up pe-
riod. Univariate analysis was performed 
using an unpaired Student’s t-test for 
quantitative variables and Pearson’s chi-
squared test for qualitative variables. 
Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated using 
logistical regression. For the multivari-
ate analysis, a regression analysis us-
ing the Cox proportional hazards model 
(Wald’s forward, step-wise method) was 
employed. In addition to sex and age, 
the analysis included all variables with 
a significance level < 0.1 in the uni-
variate analysis. Risks and confidence 
intervals were obtained at 95%. P < 0.05 
was considered statistically significant. 
All analyses were performed using the 
Statistical Package for the Social Sciences 
software suite (SPSS 11, IBM, Chicago, 
Illinois, USA). 
RESULTS
Development of LEA during follow-up
Of the initial cohort from the year 2000 
(n = 572), 23 were lost at the beginning of 
the first year of follow-up and excluded 
from the study. The remaining 549 indi-
viduals (340 women and 188 men) were 
observed for an average of 6.26 years, 
resulting in a total of 3 489 person-years 
(PY) observed. During this period, 21 
individuals or 3.8% of the cohort, includ-
ing 11 men (5.5%) and 10 women (2.9%), 
suffered one or more LEAs. The LEA 
incidence rate per 1 000 PY was 6.02 (8.65 
in men and 4.50 in women). 
Baseline cohort characteristics by 
presence/absence of LEA
Table 1 shows a comparison of the 
diabetic cohort’s socio-demographic and 
clinical characteristics at baseline by 
presence or absence of LEA over the 
follow-up period using univariate analy-
sis. Of the 25 characteristics examined, 
only nine showed a statistical association 
(P < 0.05) with risk of LEA: having insu-
lin therapy; having a level of HbA1c ≥ 
8%; being diagnosed with ischemic heart 
disease; ≥ 10 years of diabetes; being 
diagnosed with any of the three chronic 
diabetes-related microvascular compli-
cations (neuropathy, nephropathy, and 
retinopathy); having an ascending level 
of glucose; and having an ascending 
level of HbA1c.
Over the seven-year follow-up period, 
50% of the 12 diabetic individuals who 
had an LEA prior to 2001 had a ream-
putation (indicating a 52.30 times higher 
risk of LEA (P < 0.0001) for diabetic 
patients who had a previous amputation 
versus those who did not), and 75% of 
those with reamputations died during 
the follow-up period. Having a previous 
foot ulcer was also a risk factor for LEA, 
with those suffering from this condition 
54.6 times more likely to undergo an 
amputation.
There were no differences in the risk of 
LEA for age, education, health insurance 
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status, living with or without a partner, 
being a current or former smoker, body 
mass index (BMI), or lipid levels. No as-
sociation was found between risk of LEA 
and being diagnosed with hypertension 
or myocardial infarction. 
Cox proportional hazards models 
The results of multivariate analysis 
using six different Cox proportional haz-
ards model are shown in Table 2. Models 
1 and 2 measured the variables (con-
tinuous and categorical, respectively) 
with significance < 0.1 in the univari-
ate analysis, excluding insulin therapy 
and presence of chronic microvascular 
complications (neuropathy, nephropa-
thy, and retinopathy), and adding age 
and sex. Models 3 and 4 measured the 
same set of variables as Models 1 and 2, 
respectively, plus insulin therapy. Model 
5 measured the same variables as Mod-
els 3 and 4, plus presence of chronic 
microvascular complications. Model 6 
measured the same variables as Model 
5, plus “having a previous amputation.” 
Results indicated insulin therapy, male 
sex, and HbA1c ≥ 8% were indepen-
dently associated with LEA until the 
addition of chronic microvascular com-
plications (in Model 5), which elimi-
nated the HbA1c variable as a predicting 
factor. In this model, neuropathy and 
nephropathy were also eliminated as 
risk factors, and retinopathy emerged as 
the greatest predictive factor. In Model 
6, having a previous amputation elimi-
nated all other variables as predicting 
factors except insulin therapy.
DISCUSSION
While studies have been published 
on the frequency of diabetes in Latin 
America (1), and prevalence can be esti-
mated from primary data in a significant 
number of countries in the region (14), 
very few research studies have been 
conducted on the prevalence and inci-
dence of diabetic neuropathy and LEA 
associated with diabetes. Many authors 
have noted the scarcity of research on 
this diabetic complication in develop-
ing countries, including Latin America 
(15–17). Motivated by the increased fre-
quency of diabetes, Moxey et al. (16) 
conducted a literature review from 1989 
to the present to learn about global 
variability in incidence of LEA. They 
identified a total of 48 studies indexed 
in PubMed and the Cochrane Library, 
none of which were conducted in Latin 
America. With the aim of improving 
diabetic care, the Latin American Diabe-
tes Association (Associación Latinoameri-
cana de Diabetes, ALAD) (17) developed 
a guide for the management of diabetic 
polyneuropathy that presents the epide-
miology of this complication for some 
countries (Argentina, Brazil, Colombia, 
and Mexico) utilizing a limited number 
of prevalence data. These data were 
generated using a variety of methodolo-
TABLE 1. Characteristics of a diabetes patient cohort (n = 572)a at baseline (year 2000) by 












 Sex: male (%) 52.4 35.6 0.163d 1.99 (0.83–4.77)
 Age (years) 
    ≥ 65 (%) 38.1 31.8 0.546d 1.32 (054–3.24)
  Mean ±SDe 60.6 ± 12.0 58.3 ± 12.8 0.425f 1.02  (0.97–1.06)
 Living without partner (%) 38.1 35.0 0.774d 1.14 (0.46–2.80)
 < 7 years of schooling (%) 90.5 84.8 0.754g 0.59 (0.14–2.58)
 Uninsured (%) 4.8  5.9 0.831g 0.80 (0.10–6.17)
Clinical parameters
Current or former smoker (%) 47.6 40.9 0.540d 1.31 (0.55–3.15)
Years of diabetes (mean ±SD) 12.9 ± 6.6 6.9 ± 6.9 < 0.001f 1.07 (1.01–1.14)
Age of diabetes onset (years)  
 (mean ±SD) 47.6 ± 12.6 51.3 ±12.6 0.185f 1.07 (0.97–1.07)
With insulin therapy (%) 90.5 36.1 < 0.001g 16.79 (3.87– 72.9)
Body mass index ≥ 30 (kg/m2)
  (%) 35.0 43.5 0.449d 0.70 (0.27–1.78)
 Mean ±SD 29.7 ± 5.6 30.0 ± 5.6 0.810f 0.99 (0.89–1.10)
Cholesterol ≥ 200 (mg/dL)
  (%) 75.0 59.1 0.155 2.08 (0.74–5.80)
 Mean ±SD 213.5 ± 32.7 212.8± 52.9 0.937f 0.99 (0.98–1.01)
Low HDL cholesterol (< 40 in men;  
 < 50 in women) (mg/dL) 
 % 70.0 58.9 0.320d 1.63 (0.62–4.31)
 Mean ±SD 34.6 ± 10.7 38.6 ± 13.5 0.205 0.98 (0.93–1.04)
LDL cholesterol ≥ 130 (mg/dL)
 % 53.3 45.9 0.572d 1.35 (0.48–3.77)
 Mean ±SD 127.8 ± 21.8 129.6 ± 38.6 0.857f 1.00 (0.97–1.04)
Triglycerides ≥ 150 (mg/dL)
 % 70 69.6 0.968d 1.01 (0.39–2.70)
 Mean ±SD 317.9 ± 226.3 241.5 ± 197.1 0.091h 1.00 (0.99–1.00)
Triglycerides ≥ 250 and HDL  
 cholesterol < 35 (mg/dL) (%)
40.0 22.9 0.077d 2.25  (0.89–5.62)
Glycosylated hemoglobin ≥ 8%
 % 89.5 45.0 < 0.001d 10.39 (2.37–45.43)
 Mean ±SD 10.1 ± 2.3 8.0 ± 2.2 < 0.001g 1.51 (1.20–1.89)
Glucose (mg/dL) (mean ±SD) 235.8 ± 82.7 177.3 ± 79.4 0.001g 1.01  (1.00–1.01)
Hypertension (%) 52.4 58.6 0.574d 0.78 (0.33–1.86)
Presence of comorbidity (%)
Ischemic heart disease 40.0 20.2 0.033g 2.63 (1.05–6.61)
Myocardial infarction 15.0  6.1 0.109g 2.74 (0.761–9.84)
Chronic renal failurei 14.3  6.3 0.155g 2.48 (0.69–8.83)
Diabetic nephropathyj 70.0 31.9 0.001d 4.98 (1.88–13.18)
Diabetic neuropathyk 71.4 28.9 < 0.001d 6.16  (2.35–16.17)
Diabetic retinopathy 60.0 17.9 < 0.001d 6.89 (2.73–17.39)
Foot ulcer 23.8  0.6 < 0.001g 54.58 (11.99–248.40)
Previous amputation 28.6  0.8 < 0.001g 52.30 (13.35–204.85)
a Twenty-three individuals were lost in the first year of follow-up and excluded from the study.
b Baseline (reference) group. 
c CI: confidence interval.
d Based on Pearson’s chi-squared test (P < 0.05).
e SD: standard deviation.
f Based on Student’s t-test (P < 0.05).
g Based on Fisher’s exact test (P < 0.05).
h Based on Mann-Whitney U test (P < 0.05).
i Glomerular filtration rate < 60 mL/min /1.73 m2.
j Presence of micro- or macroalbuminuria, nephrotic syndrome, and/or chronic renal failure. 
k Clinical signs, symptoms, and loss of sensitivity as measured by 5.07/10-g Semmes-Weinstein monofila-
ment device.
Rev Panam Salud Publica 32(3), 2012 195
Laclé and Valero-Juan • Diabetes-related lower-extremity amputation in Costa Rica Original research
gies (cross-sectional descriptive studies, 
case-control studies, and longitudinal 
studies) (18–21), in different health care 
settings (primary care and hospital-
level) (18–22), among patients with spe-
cial clinical characteristics (patients with 
foot ulcers) (23), and thus are not easily 
comparable.
The relative absence of published data 
in Latin America should not be inter-
preted as evidence that the diabetic foot 
is a minor problem in this region. On 
the contrary, it is a serious public health 
problem (24–26), and one that can be 
prevented (27). According to ALAD (17), 
34.7% of diabetic patients in Argentina 
have diabetic polyneuropathy; 58.2% of 
those in Brazil have diabetic foot compli-
cations; 13% of diabetic patients in Chile 
with foot injuries required amputation; 
and in Mexico, between 2004 and 2005, 
hospital discharges for diabetic foot in-
creased by 10% and the number of am-
putations increased by 4%. 
The current study is the first in Costa 
Rica to investigate LEA incidence in 
diabetic patients at the community level, 
and the associated risk factors. The re-
sults provide information for identifying 
diabetic patients at high risk of amputa-
tion in monitoring and health surveil-
lance, which could help prevent this 
complication in the primary health set-
ting. The incidence rate of LEA was 6.02 
per 1 000 PY. 
In the general population, and within 
the diabetic population, the rate of LEA 
varies by geographic location, ethnic 
group, and type of community (rural/
urban) (28–31). For developing coun-
tries, reported incidence rates for LEA 
secondary to diabetes vary from 13.7 
to as high as 18.0 per 1 000 PY, as re-
ported in studies conducted in the 1990s 
among Pima Indians (32, 33). In devel-
oped countries, the rates range from 1.7 
to 2.9 (3, 34–37).
While several studies in developing 
countries provide hospital statistics, 
there is very little indexed literature 
comparable with community-based re-
sults, especially for Latin America coun-
tries. The third edition of the Inter-
national Diabetes Federation Diabetes 
Atlas (38) provides data on LEA inci-
dence in the diabetic population for two 
countries in the region: Brazil (1.81 per 
1 000 PY) (21) and Barbados (9.36 per 
1 000 PY) (39). The data from Brazil are 
from a study conducted in Rio de Janeiro 
that estimated the rate of LEA using 
a capture-recapture technique and re-
gional amputee registries, and found an 
annual rate of LEA incidence of 1.8 per 
1 000 PY (21), a prevalence similar to that 
in developed countries. Those results 
conflict with data presented in the 2000 
Annual Report of the Municipal Health 
Secretariat for the city of Rio de Janeiro 
(40) that showed 73.2% of LEAs occurred 
in people with diabetes, indicating an 
LEA incidence of 8.8 per 1 000 diabetic 
individuals—a rate similar to that in Bar-
bados, and higher than the rates found in 
the current study.
The results of the current study on 
LEA incidence in Costa Rica are similar 
to those found in research conducted 
15 years ago in a predominantly white 
population in the United States (41), 
and in European countries such as Ger-
many (which indicated a rate of 5.4 per 
1 000 PY) (42). Currently, however, in 
both North American and Europe, LEA 
incidence has dropped dramatically, to 
much lower rates than those found in 
Costa Rica, primarily because of pro-
grams aimed at improving the diabetic 
diet, and revascularization. The drop in 
LEA prevalence can be seen in France 
(which has a current rate of 3.78%) (43); 
Great Britain (2.85 per 1 000 PY) (44); the 
United States (0.8 per 1 000 PY) (45); and 
other countries (3, 35). While Costa Rica 
has a good health system (46), accord-
ing to epidemiological indicators, it is 
not addressing LEA incidence with the 
state-of-the-art measures that have been 
shown to lower rates in other countries. 
The level of LEA incidence found in 
the current study for a low-income area 
of Costa Rica is similar to that found 
in economically disadvantaged popula-
tions in developed countries, such as 
African Americans in the United States, 
among whom LEA incidence rates were 
as high as 8.3/1000 in 1996 but dropped 
to 5.3/1000 by 2002 (45). Another study, 
conducted along the U.S.–Mexico bor-
der in Texas (47), showed that diabetic 
people who lived near the border had 
higher incidence (5.36 per 1 000 PY) than 
those further inside the state (3.99 per 
1 000 PY). According to the researchers, 
the higher incidence among the border 
population was most likely related to a 
lower level of education, a low income, 
not having medical insurance, and other 
barriers to health care access. The co-
hort in the current Costa Rican study is 
poorly educated with low-income levels 
but has good access to health services, 
which could explain why LEA incidence 
TABLE 2. Results of six Cox proportional hazards models incorporating 
various characteristics of a diabetes cohort (n = 572a) followed up for 
seven-year period, Costa Rica, 2001–2007
Characteristics
Hazard 
ratio 95% CIb P-value
Model 1 (continuous values)
 Sex: male  3.81 1.41–10.29 0.0083
 HbA1cc (%)  1.47 1.19–1.83 0.0005
 Years of diabetes  1.08 1.02–1.15 0.0070
Model 2 (categorical values)
 Sex: male  3.02 1.17–7.77 0.0220
 HbA1c ≥ 8%  1.95 1.23–3.09 0.0043
  ≥ 10 years of diabetes  2.01 1.18–3.40 0.0100
Model 3 (continuous values)
 Sex: male  3.62 1.38–0.01 0.0088
 HbA1c (%)  1.32 1.05–0.02 0.0187
 Years of diabetes  1.07 1.01–0.03 0.0302
 With insulin therapy  6.48 1.38–0.02 0.0181
Model 4 (categorical values)
 Sex: male  2.91 1.14–7.38 0.0249
 HbA1c ≥ 8%  8.85 1.97–39.79 0.0045
 With insulin therapy  5.07 1.12–22.87 0.0346
Model 5 
 Sex: male  2.69 1.06–6.81 0.0375
 With insulin therapy  9.18 2.00–42.09 0.0043
 With diabetic retinopathy  3.44 1.29–9.17 0.0136
Model 6 
 With insulin therapy 10.95 2.47–48.48 0.0016
 With previous amputation  16.58 5.30–51.80 0.0000
a Twenty-three individuals were lost in the first year of follow-up and excluded from the study. 
b CI: confidence interval.
c Glycated hemoglobin.
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rates in this population are similar to 
those found among poor populations in 
developed countries. 
With regard to sex, LEA incidence in 
the Costa Rican community was higher 
in men, a finding that correlates with 
other international studies (3, 28–33, 39, 
45). In other studies conducted in Latin 
America, the frequency of LEA was also 
found to be more prevalent in males (48). 
While there were not significant differ-
ences by sex in the univariate analysis 
of the current study, when sex was in-
corporated into the six Cox proportional 
hazard models it becomes an indepen-
dent risk factor in four of them, together 
with HbA1c ≥ 8%, years of diabetes, 
use of insulin, and having retinopathy. 
In five of the multivariate models, the 
risk of being male versus female varied 
from 26% to 40%, according to the dif-
ferent variables included in the models. 
The risk was higher in the model where 
age, HbA1c level, and years of diabetes 
were used as continuous variables. This 
risk was only eliminated when having a 
previous amputation was incorporated 
into the model—a finding consistent 
with previous studies (49)—probably be-
cause having a previous amputation was 
shown here and in other studies (50) to 
be the strongest risk factor for LEA. Sev-
eral hypotheses were considered to ex-
plain why males are more at risk in this 
cohort. The authors believe the higher 
risk for men is mainly due to barriers 
associated with access to health care, 
one of which could be men’s reluctance 
to seek medical consultations if they do 
not perceive themselves to be critically 
ill. Also, in the area studied in Costa 
Rica, much of the employment of men is 
informal, leaving them largely excluded 
from Costa Rica’s social security system 
and thus lacking good access to care 
when serious health events occur. What-
ever the reasons, outpatient statistics of 
the health care system confirm that men 
utilize health services less than women 
(51). Therefore, delayed diagnosis and/
or deficient routines of medical care may 
be contributing to the higher incidence 
of LEA in males in Costa Rica, indicat-
ing a potential need for the health care 
system to devise a primary care strategy 
that help ensure that men with diabetes 
receive good care. 
Disease progression (years of diabetes) 
and elevated HbA1c, which are known 
risk factors for chronic complications 
of diabetes (6, 33), were also present as 
independent risks in the multivariate 
analysis. The finding that use of insulin 
was a risk factor is of particular interest. 
It is known that after 10 years of disease 
progression, most patients need insulin 
therapy, and that the more years of 
disease progression, the greater likeli-
hood of insulin use. In Model 3, when 
treatment with insulin was included, 
it had a higher independent risk than 
elevated HbA1c and years of diabetes. 
Model 4 demonstrates the colinearity 
between progression of the disease and 
insulin therapy: when years of diabetes 
is included in the model as a categori-
cal variable (“≥ 10 years of diabetes”), 
it disappears as a risk, but the risk of 
insulin therapy remains the same. When 
the three chronic microvascular compli-
cations are incorporated into the model, 
years of diabetes and HbA1c level are 
eliminated as risks, diabetic retinopathy 
emerges as an important risk factor, and 
insulin therapy remains as a high risk. 
When the variable of previous amputa-
tion is incorporated, only use of insulin 
remains as a risk (all other risk factors 
are eliminated). 
Therefore, a typology of risk for ampu-
tation in diabetic patients would be male 
patients with 10 or more years of diabe-
tes and an average HbA1c ≥ 8% who use 
insulin and have diabetic retinopathy, 
but those most at risk are patients with 
insulin therapy—and their risk increases 
if they have had a previous amputation. 
These factors should be considered as 
indicating very high risk for diabetic pa-
tients and, in turn, signaling the need for 
close monitoring by health care profes-
sionals. Having incidence of any disease 
as an indicator in a primary care setting 
allows for measurement of the impact of 
interventions made in a specific region 
by comparing incidence through points 
in time. For example, the data generated 
by the current research will allow any 
studied health area to monitor the qual-
ity of comprehensive care of diabetic 
patients using incidence of LEA as an 
indicator.
Recommendations
Diabetic foot care is considered a fea-
sible intervention with a high level of 
cost-effectiveness for developing coun-
tries (15). Therefore, factors that hinder 
the proper care of diabetic patients 
should be identified and addressed, to 
reduce medical complications, along 
with the associated individual and so-
cial burdens. In addition to barriers to 
accessing health care and education at 
all levels, these factors include the lack 
of follow-up records of patients and 
monitoring of complications (15, 52). 
It is well known that valid and reliable 
health statistics are essential for plan-
ning and implementing health policy in 
all settings. Almost all LEAs are done in 
hospital settings, so they could be easily 
and properly registered in hospital dis-
charge data, making incidence of LEA 
a valuable indicator in decision-mak-
ing to improve the quality of care for 
diabetic patients in developing coun-
tries. This indicator has been previously 
used in control programs on quality 
of care for people with diabetes con-
ducted in Latin America (52), and some 
countries, such as Chile, have proposed 
LEA as an indicator for monitoring 
and evaluating some of the priority 
components of diabetic patient man-
agement, using the QUALIDIAB-Chile 
program (http://qualidiabchile.minsal.
cl/) (53). Future research evaluating 
the efficacy of diabetic care in terms 
of survival, function/disability, and 
quality of life, to measure diabetes’ 
impact on individuals, the health sys-
tem, and the economic development 
of Latin American countries, is also 
recommended.
Conclusions
These results and the information in 
the consulted literature show the high 
frequency and importance of LEA as-
sociated with diabetes in Costa Rica and 
elsewhere in Latin America. Although 
the data can not be generalized to all of 
Costa Rica, they can be used as an esti-
mate of what is happening in the met-
ropolitan area of San José (especially the 
low-income areas), where 75% of Costa 
Ricans live. They may also help in plan-
ning intervention programs targeting 
prevention of LEA in diabetic patients at 
the primary, secondary, and/or tertiary 
level, including those focusing on dis-
ability, rehabilitation, and prosthetics, 
with the ultimate end of reducing the 
number of amputations. 
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Objetivo. Analizar la incidencia y los determinantes de la amputación de 
extremidades inferiores (AEI) en personas diabéticas de una comunidad con bajos 
ingresos de Costa Rica. 
Métodos. Se recopilaron datos sobre la incidencia de la AEI durante un período de 
seguimiento de siete años (del 2001 al 2007) en una cohorte de pacientes diabéticos 
(n = 572). Se analizaron los factores de riesgo usando el modelo de regresión de Cox 
de riesgos proporcionales y los valores de referencia del año 2000 de las variables 
(características sociodemográficas, comorbilidad, control metabólico, tratamiento y 
complicaciones microvasculares crónicas). 
Resultados. La incidencia de la AEI fue de 6,02 por 1 000 personas-año (8,65 en 
varones y 4,50 en mujeres). Los factores de riesgo conocidos (sexo, años de evolución 
de la diabetes, glucohemoglobina [HbA1c] elevada, retinopatía, tratamiento con 
insulina y amputación previa) fueron muy significativos. 
Conclusiones. Los pacientes diabéticos costarricenses con mayor probabilidad de 
sufrir una AEI fueron los varones con 10 o más años de evolución de la diabetes 
y un promedio de HbA1c ≥ 8% que eran tratados con insulina y padecían una 
retinopatía diabética. Los pacientes en tratamiento con insulina presentaban el mayor 
riesgo, especialmente los que habían sufrido una amputación anterior. Los pacientes 
diabéticos con el perfil descrito anteriormente deben considerarse como de riesgo 
muy elevado de AEI y deben ser seguidos de cerca por el sistema de atención de 
salud. 
Diabetes mellitus tipo 2; extremidad inferior; amputación; factores de riesgo; 
complicaciones de la diabetes; Costa Rica.
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Incidencia y factores de 
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